How Tysabri Use Relates to Progressive Multifocal Leukoencephalopathy: A Symptom and Timeline Guide
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Targeted Risk Assessment
If you or a loved one is taking Tysabri and experiencing new neurological symptoms like vision changes, weakness, or confusion, it's important to understand the potential link to Progressive Multifocal Leukoencephalopathy (PML). Over decades of pharmacovigilance, the medical community has recognized this rare but serious condition as a known risk of Tysabri therapy. This research update covers the typical timeline of symptom onset, the FDA's warning, and what monitoring looks like in practice.
Tysabri and PML: A Documented Association
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients have developed this infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals should monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML, and Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Clinical Evidence and Risk Factors
In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). FDA adverse-event reports from the FAERS database list fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, drug ineffective, urinary tract infection, pain, balance disorder, hypoesthesia, pain in extremity, muscular weakness, nasopharyngitis, nausea, dizziness, mobility decreased, stress, cognitive disorder, muscle spasms, depression, and arthralgia as the most frequently associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not among the most frequently reported events in this database, its occurrence is a known serious risk.
Mechanistic Pathway and Causation Considerations
The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the brain, thereby reducing inflammation in multiple sclerosis. However, this immunosuppressive effect also impairs immune surveillance against JC virus, allowing reactivation of latent JCV and subsequent development of PML. The risk is highest in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus. Longer treatment duration, especially beyond 2 years, increases the cumulative risk, and prior use of immunosuppressants further compromises the immune system. The adequacy of warnings regarding Tysabri and PML is addressed by the boxed warning and the TOUCH Prescribing Program. The boxed warning clearly states that Tysabri increases the risk of PML, identifies risk factors, and instructs healthcare professionals to monitor patients and withhold dosing at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH program restricts distribution to ensure that prescribers and patients are informed about the risk and that monitoring occurs. However, despite these warnings, PML cases have occurred, raising questions about whether the warnings are sufficient to prevent harm. Causation-related considerations for affected patients involve establishing a link between Tysabri exposure and PML. The known risk factors—anti-JCV antibodies, treatment duration, and prior immunosuppressant use—provide a basis for assessing causation. In patients who develop PML while on Tysabri, the temporal relationship between exposure and harm is critical. The timeline between exposure and documented harm can vary. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that PML can develop after varying durations of treatment, and early detection through monitoring is essential. For affected patients, establishing causation requires demonstrating that Tysabri was a substantial factor in the development of PML, considering alternative causes such as other immunosuppressive conditions. The presence of anti-JCV antibodies and the absence of other immunosuppressive therapies can support causation. The FDA's boxed warning and clinical trial data provide evidence that Tysabri increases the risk of PML, which can be used in legal or medical contexts to argue causation.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the FDA warning about Tysabri and PML?
The FDA has issued a boxed warning for Tysabri (natalizumab) stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus that often leads to death or severe disability. The warning also identifies risk factors such as anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use.
How does Tysabri cause PML?
Tysabri works by blocking the migration of immune cells into the brain, which reduces inflammation in multiple sclerosis. However, this also impairs the brain's ability to fight the JC virus, allowing it to reactivate and cause PML. The risk is higher in patients with anti-JCV antibodies, longer treatment duration, and prior use of immunosuppressants.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.